Greenleaf Trust Has $760,000 Position in Regeneron Pharmaceuticals, Inc. $REGN

Greenleaf Trust lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.3% during the second quarter, HoldingsChannel reports. The institutional investor owned 1,448 shares of the biopharmaceutical company’s stock after selling 464 shares during the period. Greenleaf Trust’s holdings in Regeneron Pharmaceuticals were worth $760,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in REGN. Brighton Jones LLC grew its holdings in Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares during the last quarter. NBC Securities Inc. acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $78,000. Merit Financial Group LLC grew its holdings in Regeneron Pharmaceuticals by 87.7% during the first quarter. Merit Financial Group LLC now owns 1,629 shares of the biopharmaceutical company’s stock valued at $1,033,000 after purchasing an additional 761 shares during the last quarter. Portside Wealth Group LLC grew its holdings in Regeneron Pharmaceuticals by 7.6% during the first quarter. Portside Wealth Group LLC now owns 776 shares of the biopharmaceutical company’s stock valued at $492,000 after purchasing an additional 55 shares during the last quarter. Finally, Gilman Hill Asset Management LLC grew its holdings in Regeneron Pharmaceuticals by 1.9% during the first quarter. Gilman Hill Asset Management LLC now owns 5,303 shares of the biopharmaceutical company’s stock valued at $3,363,000 after purchasing an additional 100 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the topic of several analyst reports. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a “sector perform” rating in a report on Monday, August 4th. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a report on Monday, June 9th. Sanford C. Bernstein increased their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a report on Wednesday, August 27th. Canaccord Genuity Group restated a “buy” rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Finally, Jefferies Financial Group raised their price objective on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research note on Wednesday, August 27th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $817.67.

Regeneron Pharmaceuticals Stock Up 0.0%

Shares of REGN stock opened at $600.00 on Friday. The stock has a market cap of $63.59 billion, a P/E ratio of 15.12, a price-to-earnings-growth ratio of 1.92 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,038.81. The stock has a fifty day moving average price of $571.38 and a 200 day moving average price of $568.39. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period last year, the business earned $11.56 earnings per share. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.